Tuesday Jan 17 | Seeking Alpha
Biogen: A 'Decimated' Pipeline?
You don't want coverage like this : "Biogen CEO Tries to Refill Early-Stage Pipeline He Decimated." That would be George Scangos: . . .Scangos and his research chief eliminated about 17 early-stage drug projects in 2010 and last year to hone the company's focus, leaving it with only about four early-stage compounds.